Development of self-assembling peptide nanovesicle with bilayers for enhanced EGFR-targeted drug and gene delivery

详细信息    查看全文

• 作者：Xiaofei Liang^a ; ¹ ; Bizhi Shi^a ; ¹ ; Kai Wang^a ; Mingliang Fan^a ; Dejin Jiao^b ; Junping Ao^a ; Na Song^b ; ^{snlxf@shu.edu.cn" class="auth_mail" title="E-mail the corresponding author} ; Chun Wang^c ; Jianren Gu^a ; Zonghai Li^a ; ^{zonghaili@shsmu.edu.cn" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Peptide ; Tumour-targeted nanocarrier ; Gene and drug delivery ; Liposome ; Cancer therapy
• 刊名：Biomaterials
• 出版年：2016
• 出版时间：March 2016
• 年：2016
• 卷：82
• 期：Complete
• 页码：194-207
• 全文大小：5001 K

文摘

Development of rational vectors for efficient drug and gene delivery is crucial for cancer treatment. In this study, epidermal growth factor receptor (EGFR)-binding peptide amphiphile (PA) were used as the primary bilayer skeleton material to construct ultra-stable self-assembling peptide nanovesicle (SPV). The resulted EGFR-targeted SPV (ESPV) could efficiently encapsulate therapeutic cargos (drugs or small interfering RNAs [siRNAs]) or labelled fluorescent cargo (quantum dots [QDs]) and exhibited excellent affinity for EGFR-positive cancer cells. Moreover, ESPV could deliver more drug or plasmid DNA to tumour sites and promote gene expression (a three-fold ratio of ESPVs vs cationic liposomes). Notably, the individual delivery or co-delivery of doxorubicin (DOX) and the acetylcholinesterase (AChE) gene via the ESPVs resulted in excellent drug/gene delivery both in vitro and in vivo and exerted a significant growth-suppressing effect on a liver cancer xenograft. This nanoscale, targeted cargo-packaging technology may provide a new strategy for the design of highly targeted cancer therapy vectors.